Skip the wait and schedule your appointments online or through MyChart.

COVID Vaccine Now Available for Ages 6 months+ – Learn More

Research & Innovation

AMG 334 – 20190389

Clinical Trials

Phase 4, Open-label Study to Evaluate Treatment Satisfaction with Erenumab in Patients with Migraine (AMG 334 – 20190389)

Physician & Study Coordinator

Synopsis: This study is being done to analyze treatment satisfaction with erenumab as a preventive treatment in adult patients with episodic migraine (EM) or chronic migraine (CM) currently on 1 standard of care migraine prevention therapy.

The drug(s) used in this study is: Erenumab. Erenumab is an antibody that helps prevent migraine by blocking the receptor for calcitonin gene-related peptide (or CGRP), a substance in your body that is released during migraine attacks

It will evaluate how satisfied you are with erenumab treatment, whether you feel that your migraine gets better or worse or stays the same with erenumab treatment, and the effect of erenumab on how your migraine affects your day-to-day activities.


Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years
  • History of migraine (with or without aura) for ≥ 12 months before screening
  • ≥ 4 migraine days per month on average across the 3 months prior to screening
  • Treatment with 1 oral migraine preventive medication

Exclusion Criteria

  • History of cluster headache or hemiplegic migraine headache
  • Unable to differentiate migraine from other headaches
  • Evidence of substance-related disorders
  • Active chronic pain syndromes (e.g., fibromyalgia and chronic pelvic pain)
  • No therapeutic response with > 3 migraine preventive medication categories